Nuwellis, Inc. To Announce First Quarter 2023 Financial Results on May 9, 2023
Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company, is set to release its Q1 2023 financial results on May 9, 2023.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company, is set to release its Q1 2023 financial results on May 9, 2023. The company will hold a conference call and webcast at 9:00 AM ET to discuss the financial results and provide a general business overview. Investors can access the live webcast on Nuwellis' Investors page or by calling the designated numbers provided for U.S. and international participants.
Nuwellis specializes in treating fluid overload issues with its Aquadex SmartFlow® system, aimed at transforming the lives of affected patients. This system is designed for use in both outpatient and inpatient settings under physician supervision.
Positive
- Upcoming financial results release could provide insight into company performance.
- Potential for growth through commercialization of the Aquadex SmartFlow system.
Negative
- None.
Details
News Market Reaction – NUWE
The recorded move for NUWE in the trading session of this news was -2.40%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
MINNEAPOLIS, April 18, 2023 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, announced today that its first quarter 2023 financial results will be released on Tuesday, May 9, 2023. The company will host a conference call and webcast at 9:00 AM ET, during which management will discuss the company’s financial results and provide a general business overview.
To access the live webcast, please visit the Investors page of the Nuwellis website at https://ir.nuwellis.com. Alternatively, you may access the live conference call by dialing 1-833-816-1404 (U.S) or 1-412-317-0497 (international) and using the conference ID: 10177112. An audio archive of the webcast will be available following the call on the Investors page at https://ir.nuwellis.com.
About Nuwellis
Nuwellis, Inc. (Nasdaq: NUWE) is a medical technology company dedicated to transforming the lives of patients suffering from fluid overload through science, collaboration, and innovation. The company is focused on commercializing the Aquadex SmartFlow® system for ultrafiltration therapy. Nuwellis is headquartered in Minneapolis, with a wholly owned subsidiary in Ireland. For more information visit www.nuwellis.com or visit us on LinkedIn.
About the Aquadex SmartFlow® System
The Aquadex SmartFlow system delivers clinically proven therapy using a simple, flexible and smart method of removing excess fluid from patients suffering from hypervolemia (fluid overload). The Aquadex SmartFlow system is indicated for temporary (up to 8 hours) or extended (longer than 8 hours in patients who require hospitalization) use in adult and pediatric patients weighing 20 kg or more whose fluid overload is unresponsive to medical management, including diuretics. All treatments must be administered by a health care provider, within an outpatient or inpatient clinical setting, under physician prescription, both having received training in extracorporeal therapies.
CONTACTS
INVESTORS:
Vivian Cervantes
Gilmartin Group LLC
ir@nuwellis.com
MEDIA:
Annika Parish
Health+Commerce
annika@healthandcommerce.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.